Abstract 5291
Background
The Irish Longitudinal Study on Ageing (TILDA) estimates that 13.1% of the Irish population is vitamin D3 deficient, compared with less than 6% of the US population surveyed in the National Health and Nutrition Examination Survey (NHANES). In recent years, numerous studies have shed light on a potential role for vitamin D3 in breast cancer risk modification and prognosis. We set out to assess the prevalence and clinical significance of vitamin D3 deficiency in women with breast cancer receiving chemotherapy in an Irish oncology dayward.
Methods
Retrospective chart review was conducted to collect data incuding patient age, cancer stage at diagnosis, date of treatment initiation and 25-hydroxy vitamin D3 (25(OH)D3) levels at start of treatment. Vitamin D3 deficiency was defined as a value <50 nmol/L. Charlson Comorbidity Index (CCI) was caluclated for all patients. Mean 25(OH)D3 levels by season (autumn, winter, spring, summer) were also caluclated. As the data set was not normally distributed, inter-group comparison was conducted using the Kruskal-Wallis Test with p < 0.05 considered significant.
Results
41 women had available baseline 25(OH)D3 levels and were included. 66% were deficient in 25(OH)D3 at baseline. The prevalence of vitamin D3 deficiency showed substantial seasonal variation, being highest in the winter months (88%) and lowest in the summer months (0%). Furthermore, mean 25(OH)D3 levels were lowest in the winter months (29.0nmol/L + 13.8) and highest in the summer months (66.3nmol/L + 11.5). The difference in mean 25(OH)D3 levels across the four seasons was significant (p = 0.022). Women who were deficient in vitamin D3 tended to be younger (p = 0.00001), have a higher cancer stage (p = 0.0071), and have a less favorable 10-year all cause mortality risk as indicated by their CCI (p = 0.0041).
Conclusions
We found a striking prevalence of 25(OH)D3 deficiency among women with breast cancer receiving adjuvant/neoadjuvant chemotherapy in an Irish oncology dayward. Notable seasonal variation in mean vitamin D3 levels was observed. Vitamin D3 deficiency was found to be more prevalent in younger women and was associated with a higher stage of breast cancer as well as a less favorable 10-year all cause mortality risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract